奇正藏药(002287) - 2019 Q3 - 季度财报

Financial Performance - Operating revenue for the period reached CNY 360,920,838.92, a year-on-year increase of 14.97%[8] - Net profit attributable to shareholders was CNY 73,242,433.68, reflecting a growth of 31.66% compared to the same period last year[8] - Basic earnings per share rose by 31.75% to CNY 0.1390[8] - Total operating revenue for the period reached ¥360,920,838.92, an increase of 14.94% compared to ¥313,939,505.24 in the previous period[61] - Net profit for the period was ¥73,505,397.57, representing a 31.88% increase from ¥55,770,323.44 in the prior period[64] - The company reported a total comprehensive income of ¥74,500,831.87, compared to ¥55,770,323.44, an increase of 33.54%[68] - The company reported a net profit of ¥275,417,504.37 for the current period, up 12.0% from ¥245,813,301.00 in the previous period[81] - The company achieved a profit margin of approximately 9.3% for the current period based on net profit and operating revenue[75] - The net profit for the current period was ¥265,579,490.65, up 30% from ¥204,418,012.77 in the previous period[93] - The total comprehensive income for the current period was ¥265,579,490.65, compared to ¥204,418,012.77 in the previous period, indicating a growth of 30%[93] Assets and Liabilities - Total assets increased by 19.51% to CNY 2,763,884,524.27 compared to the end of the previous year[8] - The company's net assets attributable to shareholders increased by 6.04% to CNY 2,151,827,727.38[8] - Total current assets increased to ¥1,935,999,071.29 as of September 30, 2019, up from ¥1,488,871,156.64 on December 31, 2018, representing a growth of approximately 30%[44] - Total liabilities increased significantly, with short-term borrowings rising to ¥300,000,000.00, marking a 100.00% increase[24] - Total liabilities amounted to ¥595,711,877.63, up from ¥267,538,956.74, which is an increase of approximately 122%[47] - The total liabilities increased to ¥550,686,722.72, compared to ¥354,866,576.20, marking a rise of 55.06%[60] - Total equity reached ¥2,024,924,889.77, up from ¥1,913,843,336.11, indicating a growth of 5.79%[60] - The total assets amounted to $2,268,709,912.31, with non-current assets totaling $878,515,473.11[122] - Current liabilities totaled $316,692,142.27, including accounts payable of $65,010,972.88 and other payables of $220,308,821.61[122] Cash Flow - The net cash flow from operating activities decreased by 35.18% to CNY 63,606,061.25[8] - Cash and cash equivalents increased by 210.10% to ¥1,226,500,059.66 from ¥395,511,523.60 due to the redemption of financial products and new short-term bank loans[24] - The cash flow from operating activities generated a net amount of ¥261,620,183.79, down 35% from ¥403,629,729.41 in the previous period[94] - The total cash and cash equivalents at the end of the period reached 1,024,726,022.03, up from 54,760,145.30 in the previous period, marking a substantial increase[106] - The company reported a total operating cash inflow of 1,164,198,754.41, significantly higher than 690,108,187.90 in the last period, representing an increase of approximately 69%[103] Expenses - Research and development expenses increased by 39.08% to ¥29,638,785.15 from ¥21,310,662.28, reflecting increased investment in new product development[24] - The company reported a 70.56% increase in management expenses, totaling ¥74,628,053.67, primarily due to higher depreciation and employee compensation[24] - Total operating costs amounted to ¥284,127,491.99, up from ¥256,259,889.05, reflecting a growth of 10.85%[61] - Sales expenses surged to ¥24,268,846.94, a significant increase from ¥2,859,834.39, reflecting a rise of 748.5%[72] - The company's management expenses increased to ¥42,997,276.14 from ¥36,623,397.59, representing a rise of 17.5%[86] Shareholder Information - The company reported a total of 15,645 common shareholders at the end of the reporting period[12] - The largest shareholder, Gansu Qizheng Industrial Group Co., Ltd., held 68.76% of the shares[12]